

Anglonordic Life Science Conference

5 May 2022

F.R. Martelet, M.D., CEO



Forward-looking statement

Important notice

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Forward looking statements

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Vivesto believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Vivesto include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Vivesto has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.


Building a Swedish based oncology-focused specialty pharma company



Listed on Nasdaq Nordic stock exchange (VIVE) with a market cap of ~\$73m (~710 MSEK)



Apealea® (paclitaxel micellar) being launched by partner in Europe; first royalties and anticipated H2 2022



Emerging portfolio focused on hard-to-treat and late-stage cancers with limited treatment options



Company transformation completed including addition of new skills to drive growth



First in-licensed drug Cantrixil Phase 2 in preparation; *'pipeline within a molecule'* potential



String of pearls' strategy to build comprehensive oncology pipeline through in-licensing & M&A


Our mission

To build a diversified pipeline focused on hard-to-treat and late-stage cancers using different mechanisms of action

Our transformation journey so far

New strategy and focus

Development of internal and in-licensed products
 Revenues from out-licensed products and technologies



Capabilities and experience to build a diversified oncology pipeline

Business Development	Partnering	Pipeline	Regulatory	Clinical	Product Development
----------------------	------------	----------	------------	----------	---------------------



Francois Martelet, MD
Chief Executive Officer



Fredrik Järsten*
Chief Financial Officer



Daniel Tesfa, MD PhD**
Chief Medical Officer



Reinhard Koenig, MD
Chief Scientific Officer



Kia Bengtsson
Head of Clinical Development



Johanna Röstin
Head of Regulatory Affairs



Kai Wilkinson, PhD
Chief Technology Officer



Head of Quality



Head of R&D and Manufacturing



Pharmacovigilance Officer

Our areas of focus

Oncology R&D

in-licensed & wholly-owned development-stage assets

- Cantrixil
- Docetaxel micellar
- Strategic pipeline development (string of pearls)



Oncology Commercial

revenues from out-licensed products and technologies


- Apealea® for ovarian cancer
- XR-17™ / XR-18 drug delivery technologies
- Animal health assets for partnering

The 'string of pearls' strategy to build critical mass

Leveraging our development, regulatory & commercial partnering skills

Evaluating a wide range of targets with multiple mechanisms of action (pre-clinical to late Phase 3)

Potential for high value exit opportunities from Phase 2



Vivesto may market products in niche cancer indications in certain markets if the economics are favorable.

Aiming to build critical mass in hard-to-treat cancers

Significantly broadened pipeline by implementing 'string of pearls' strategy

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration / approval	Commercial Launch	Geography
Apealea® (paclitaxel micellar)	Ovarian cancer	→						EU/EEA
Apealea® (paclitaxel micellar)	Ovarian cancer	→						US
Cantrixil IP	Ovarian cancer	→						Global
Docetaxel micellar	Prostate cancer	→						EU/EAA
Cantrixil New Formulation	Ovarian cancer	→						Global



Q4 report – delivering cost savings and careful cash management

Net sales of \$1.01m (9.6 MSEK)

- Drug products shipped to Elevar

Operating costs totalled \$3.31m (31.4 MSEK)

- Significant reduction since Q4 2020 and for the full year cost savings amounted to \$11.6m (110 MSEK)

Operating loss of -\$0.22m (-2.1 MSEK)

Operating cashflow of -\$4.66m (-44.6 MSEK)



- If adjusted for the non-recurring payment of \$2.63m (25 MSEK) in relation to the settlement, operating cashflow in Q4 was approx. -\$2.06m (-19.6 MSEK)

Cash and cash equivalents amounted to \$10m (97 MSEK) at the end of the quarter

No borrowings as per 31 December, implying a net liability of -\$10m (-97 MSEK)

Rights issue completed in March 2022, raising \$15.3m (151 MSEK)

Significant reduction in Opex MSEK (\$)



Multiple Catalysts to Drive Future Value

Potential Near- and Mid-Term Value Drivers



Summary

Opportunity to create a Nordic oncology powerhouse focused on hard-to-treat cancers



Capabilities and experience in place to build a diversified oncology pipeline



String of pearls strategy to build critical mass



Multiple shots on goal through diversified mechanisms of action targeting varied tumor types



A strong platform for innovative partners & high potential assets



Positioned to attract international **institutional specialist investors**



Thank you

Vivesto AB (STO: VIVE)
Vallongatan 1
752 28 Uppsala
Sweden

 +46 018-50 54 40

 IR@vivesto.com

 www.vivesto.com

 www.linkedin.com/company/vivesto-ab

 www.twitter.com/vivesto

